AI Summary of CMMNJ Meeting on 2-10-26
Summary: The meeting convened to coordinate advocacy, policy response, and outreach around recent cannabis and psilocybin legislation, home‑grow access, and related public education and fundraising efforts. The team reviewed a large bill set—highlighting Home and Medical Cannabis bills (including bill 1758) assigned to Assembly Oversight and Senate Human Services committees—and prioritized hearings with outreach to the incoming governor’s team. The group examined the psilocybin law (S2283), noting licensing categories, an 11‑member advisory board, and uncertainty whether the Department of Health or CRC will write regulations. Attendees raised equity and access concerns about the pilot research model, discussed likely RFPs for medical centers across North, Central, and South Jersey with roughly $2 million grants per program, and agreed to compile dosing and administration protocols and seek alternative funding such as opioid settlement dollars.
The team planned public‑opinion work, agreeing to pursue up to three omnibus poll questions (Stockton poll timing late March) and assigned drafting tasks and funding checks. They reviewed senior harm‑reduction fundraising (a requested ~$5,000), repurposable outreach materials, and confirmed participation in Morristown Day (June 6) and Asbury Park Pride (June 7). Other agenda items included insurance advocacy, reviving de‑scheduling letters (AR 26) with Jim Miller offering drafting help, a call for psychedelic textbook chapters (proposal deadline Feb 18, anonymity/HIPAA required), home‑grow technical guidance (100 sq. ft. canopy ~ six to ten plants, indoor/caregiver options), and handling a participant’s concerning rhetoric while emphasizing mobilizing patient testimony and legislative engagement.
14:03
Jim Miller will monitor responses to his credentialing submission and follow up as needed Ask Copilot
27:24
Wes Bridges (CRC) will connect the meeting participant with additional CRC staff for ongoing contacts. Ask Copilot
27:59
A conference room participant will investigate whether opioid settlement funds can be used to support education and harm reduction programs related to these initiatives. Ask Copilot
38:34
A conference room participant will look into opioid settlement funding opportunities as stated (owner reiterated). Ask Copilot
38:38
A conference room participant will research and prepare a summary of how other states allow medical cannabis in hospitals, including protocols and dispensing logistics. Ask Copilot
51:08
Guy will investigate the opioid settlement fund as a potential funding source for polling. Ask Copilot
55:35
Ed will draft the poll questions and circulate them for review. Ask Copilot
55:45
Meeting participants will review and comment on drafted questions via the shared email/Google Doc thread. Ask Copilot
55:48
Ed will place draft questions into the shared Google Doc for collaborative editing. Ask Copilot
58:52
Jim will draft the home‑grow poll question and submit it to the group. Ask Copilot
1:19:33
EdR will check with Stockton about any word or character limits for submitted questions. Ask Copilot
1:20:24
Jim Miller will prepare three versions (short/medium/long) of proposed questions for submission to Stockton. Ask Copilot
1:21:00
Conference room participant will draft questions in the morning and forward them to the group. Ask Copilot
1:21:13
Meeting participant will ask "the shell" to draft the insurance question for submission. Ask Copilot
1:28:22
Guy will publish or otherwise disseminate the psychedelic survey results for public review. Ask Copilot
1:35:50
Jim Miller will draft or review a letter to the governor regarding state de‑scheduling and Consumer Affairs' decision. Ask Copilot
1:36:27
The team will locate, update, and resend previously written advocacy letters from the CMMNJ blogspot to the new governor and relevant officials. Ask Copilot
1:46:36
Jim Miller will accept representation of the participant’s concerns if the participant shares contact details and consent for representation. Ask Copilot
1:54:16
Ryan will send the letter he sent to the President to the group for review and follow-up. Ask Copilot
1:54:30
A conference room participant will review Ryan’s submitted materials and pursue follow-up based on that information. Ask Copilot
1:59:51
Mike will staff and set up the Morristown Day booth on June 6, arriving for setup at 8:00. Ask Copilot
2:00:29
The team will recruit volunteers to staff the Morristown Day and Pride Festival booths. Ask Copilot
2:00:44
Conference room participant will send the textbook call and submission link to the coalition list for wider distribution. Ask Copilot
2:01:03
Guy will email the submission link to people who contact him directly about authoring chapters. Ask Copilot
2:01:05
Interested authors will submit a 1,200-word proposal by the February 18 deadline. Ask Copilot
2:07:46
Guy will add an explicit HIPAA/anonymity paragraph to the outreach language so participants understand submissions will be anonymized. Ask Copilot
2:21:19
Meeting participant (Conference room participant who spoke at 1741) will purchase a rosin press to make personal concentrates. Ask Copilot
2:26:20
EdR will address the issue of letting Guy tap into the list and managing the caveat tomorrow. Ask Copilot
2:38:03
Conference room participant will forward Ryan's letter to the group Ask Copilot
7:51
Is the employer prohibition bill intended to apply only to safety-sensitive roles like drivers? Ask Copilot
Proposed answer: It was clarified that the concern includes truck drivers (affirmative answer)
10:14
Did you follow through on contacting the incoming governor about hearings? Ask Copilot
Proposed answer: Jim Miller said he did follow through and made attempts during the transition
13:10
Who is "Sue" referenced in outreach efforts? Ask Copilot
Proposed answer: The participant clarified the reference was to Sue DeGroza
23:20
How does a patient or medical center get chosen for the pilot program? Ask Copilot
Proposed answer: The state will likely issue an RFP and medical centers/systems (regional coverage North/Central/South) will bid; programs will receive $2 million grants and each program will set participant selection criteria.
36:51
What forms of consumption will be allowed in hospital settings? Ask Copilot
Proposed answer: Smoking and vaping will likely be disallowed; hospitals are expected to use non‑inhalation forms such as tinctures or pharmacy‑prepared dosing forms.
37:31
How will hospitals handle specific strains that work for individual patients? Ask Copilot
40:09
Are SCC’s activities limited to California? Ask Copilot
Proposed answer: No; participants reported SCC activity across multiple locations, including Denver.
52:34
What are Stockton’s fees for adding questions to their omnibus poll? Ask Copilot
Proposed answer: Stockton quoted two questions for $1,200, three for $1,800, and five for $3,000.
55:57
Who conducted the poll that showed roughly 63% support for home cultivation? Ask Copilot
Proposed answer: The Rutgers Eagleton survey was identified as the source of the 63% figure.
56:50
Can Stockton count sub‑questions (e.g., form of product) within a single question? Ask Copilot
Proposed answer: The group recommended using broader, single questions now and saving specificity for later, implying sub‑questions may be less effective in this omnibus format.
1:03:40
Did you send the fundraising appeal to many people? Ask Copilot
Proposed answer: It was placed on the CMMNJ agenda and distributed to about 3,000 people.
1:08:10
What is meant by a "greenout"? Ask Copilot
Proposed answer: A "greenout" refers to overconsumption symptoms where someone may panic or have anxiety; the recommended response is to calmly monitor and support the person for a few hours, similar to psychedelic harm-reduction models.
1:11:14
When did the NRA become involved regarding firearms and cannabis policy? Ask Copilot
Proposed answer: The involvement was noted as occurring about two to three weeks earlier.
1:13:07
Did the ATF publish a regulation about unlawful users and firearms? Ask Copilot
Proposed answer: Yes; an interim final rule updating the definition was noted as being published in the Federal Register on or about January 21.
1:21:43
Should insurance cover medical cannabis? Ask Copilot
Proposed answer: The discussion clarified focus on New Jersey state programs (Senior Gold/PAD) rather than commercial health insurers, with prior bills proposed for state-level coverage.
1:27:52
Why hadn't the psychedelic survey been shared with the group originally? Ask Copilot
Proposed answer: The presenter responded that they believed they had already shared it.
1:33:40
Are the bills being discussed specific to New Jersey? Ask Copilot
Proposed answer: Yes, the bills referenced are New Jersey legislation.
1:34:47
Which state department made the scheduling decision referenced in the discussion? Ask Copilot
Proposed answer: The Department of Consumer Affairs was identified as the department involved in scheduling decisions.
1:54:24
Do you want my email address? Ask Copilot
Proposed answer: Yes; the conference room participant confirmed they have it and that it provided the meeting link.
1:58:50
Is a 10x10 (100 sq. ft.) canopy sufficient for home growing compared to plant-count limits? Ask Copilot
Proposed answer: Yes; 10x10 is a common norm and provides an amount comparable to six–ten plants.
2:02:37
Are psychedelics legal for inclusion in the textbook content? Ask Copilot
Proposed answer: No; participants noted psychedelics are Schedule I, but the textbook is an academic, educational project and will be peer-reviewed.
2:06:52
Can personal accounts of recreational LSD use that reported therapeutic benefit be included? Ask Copilot
Proposed answer: Yes; such experiences could be acceptable, provided contributions are anonymized and framed appropriately within therapeutic or research contexts.
2:20:53
Is it legal to make your own tinctures and derivatives at home? Ask Copilot
Proposed answer: One participant said they have done it for years and had not checked legality recently, and a later clarification stated producing tinctures from legally purchased cannabis and keeping receipts was presented as legal.
2:28:04
Is vaping considered smoking for institutional-use policies? Ask Copilot
Proposed answer: Participants and EdR stated vaping is not smoking because there is no actual smoke, and vaping delivers vaporized cannabis rather than smoke.
2:29:47
Was secondhand vaping considered secondhand smoke in legal rulings? Ask Copilot
Proposed answer: A participant noted a court ruling indicated secondhand vape was not treated as secondhand smoke and others agreed there is no smoke when vaping.
2:41:57
Do we still have Joanne on board? Ask Copilot
Proposed answer: Yes, Joanne is on the list and confirmed present
2:52
Introductions and informal check-in
The meeting opened with informal greetings and attendee identification. Jared I. Mancinelli announced his new apartment downtown in the Bell Telephone building and participants exchanged local residence details.
- The meeting began with introductions and Jared announcing his new downtown apartment
4:02
Preparing materials and bill packet logistics
The team discussed compiling the new list of bills for the legislature and encountered logistical problems producing materials, including a printer failure when printing the bills. Participants noted many of the new bills relate to cannabis and that printing and distribution created extra effort.
- The team identified a large set of newly introduced legislative bills, many focused on cannabis policy
- Participants noted logistics problems producing materials, including a broken printer while preparing bill packets
5:25
Review of bill topics and initial reactions
Members reviewed the emailed bill list and discussed specific policy areas, including potential employer restrictions on employee cannabis use and applicability to safety-sensitive roles like truck drivers. The group also noted provisions such as THC potency limits and regulation of cannabis beverages within the bill set.
- Discussion flagged employer ability to prohibit employee cannabis use, with attention to safety-sensitive roles like truck drivers
- Attendees highlighted proposed THC potency limits and regulation of cannabis beverages among the new bills
9:18
Legislative strategy and outreach to the incoming governor
The team confirmed that Home and Medical Cannabis legislation (including bill 1758) was introduced by Reynolds-Jackson, Singleton, and Gopal and assigned to Assembly Oversight and Senate Human Services and Senior Citizens committees, and they emphasized obtaining hearings for those bills. Jim Miller described his outreach to Governor-elect Sherrill’s team, attempts to engage through proper channels, and recent submission of credentialing materials while awaiting responses.
- Home and Medical Cannabis legislation, including bill 1758, was introduced by Reynolds-Jackson, Singleton, and Gopal and assigned to relevant committees
- Jim Miller has contacted the incoming governor’s team and submitted credentialing materials and is awaiting engagement or follow-up
16:02
Psilocybin and cannabis legislation overview
Participants reviewed multiple cannabis bills and summarized psilocybin legislation S2283, noting license types and Department of Health authority to regulate manufacture, testing, transport, delivery, sale, and purchase. The advisory board structure and questions about appointment breakdowns were raised.
- New Jersey passed a psilocybin law (S2283) that creates five license types and funds the Department of Health to license and regulate psilocybin activities.
- An 11‑member advisory board will be appointed to advise the psilocybin pilot program, with unspecified appointment breakdowns referenced in the statute.
17:50
Access and equity concerns for psilocybin pilot
The team debated whether the pilot research model will restrict access to patients without substantial resources and compared the likely commercial trajectory to past cannabis commercialization that inserted corporate intermediaries between doctors and patients. Attendees expressed differing levels of optimism about avoiding cannabis‑style outcomes.
- The pilot psilocybin program is structured as research and currently does not provide broad patient access, raising equity concerns that wealthy patients may be prioritized.
21:22
Advisory board, timeline, and regulatory responsibility
Attendees discussed the advisory board’s role, expected pilot timelines (approximately one year), and whether recommendations will go to the CRC or Department of Health, with a leaning toward the Department of Health handling implementation. The advisory board will advise on use of natural mushrooms versus psilocin.
23:20
Pilot selection and funding mechanics
The group explored how patients and medical centers will be selected, concluding the state will likely issue RFPs and regional medical systems will bid for roughly $2 million grants each, leaving participant selection to individual programs.
- The state will likely select pilot sites through an RFP process targeting regional coverage and will offer approximately $2 million grants per program.
25:08
CRC engagement, hospital/prison access, and protocols
A participant reported a meeting with CRC staff (Wes Bridges) and emphasized the need for hospital and institutional dosing/administration protocols and provider education, noting existing resources from organizations like the Society of Cannabis Clinicians. The idea of piloting medical cannabis in correctional facilities was also raised.
- Participants emphasized using existing dosing and administration guidelines (e.g., Society of Cannabis Clinicians) to accelerate hospital and institutional access rather than redoing foundational research.
- Several attendees committed to researching external models and funding sources, including other states’ hospital protocols and opioid settlement funds, to inform local implementation.
30:47
Social equity metrics and funding opportunities
The CRC’s published review and social equity metrics were referenced, including percentages of diversely owned businesses and training academy enrollment; participants discussed the limited spend of social equity funds and suggested exploring opioid settlement funds as an additional financing source.
- The Cannabis Regulatory Commission reports social equity metrics and programs, including a training academy and diversity statistics for licensed businesses.
33:59
Comparative state policies and logistics for hospital dispensing
Attendees requested research into how states with hospital access (e.g., California, Maryland, Minnesota, Washington) handle non‑inhalation forms, pharmacy dispensing, and protocols, and agreed someone would compile these operational details for New Jersey implementation.
39:43
SCC contacts and event planning
Conference-room participants reported active relationships with SCC and plans to co-host a virtual event on psychedelics, noting SCC’s broader geographic activity beyond California. The group acknowledged existing memberships and regional engagement such as a Denver presentation.
- The team is collaborating with SCC and planning a virtual event on psychedelics with SCC involvement.
40:30
Late arrivals and attendance checks
Participants noted late joiners and confirmed attendee presence, with brief remarks that the secretary and Trina had attended. The discussion moved quickly from roll call to operational items.
41:08
Technology disruption and resolution
Multiple participants experienced audio echo and duplicate Zoom sign‑ins when Ed joined, prompting troubleshooting advice, participant guidance on removing duplicate connections, and confirmation that the audio issue was resolved. The group then moved on to substantive agenda items.
41:23
Federal update and legislative context
The group reviewed that the Justice Department had not advanced marijuana rescheduling despite prior directives and noted historical inaction on similar instructions. Attendees expressed concern but did not identify new federal steps.
- There is no new federal action to restart marijuana rescheduling despite prior direction to the Justice Department.
46:26
Polling options, costs, and purpose
The team reviewed Stockton’s offer to add paid questions to an omnibus poll, discussed standalone poll costs (~$25,000 for 30 questions), and compared prior Rutgers Eagleton results showing 63% support for home grow. Funding options and grant opportunities were raised, including NJEDA and opioid settlement funds.
- Stockton offered omnibus poll slots: two questions for $1,200, three for $1,800, and five for $3,000, with the omnibus fielding in late March.
- A Rutgers Eagleton survey from March 2023 found about 63% support for home cultivation in New Jersey.
- Guy will investigate the opioid settlement fund as a potential funding source.
54:12
Question drafting and allocation
Participants agreed to prioritize two or three questions covering insurance, home cultivation, and institutional access. Ed volunteered to draft questions and place them in a shared Google Doc; Jim volunteered to write the home‑grow question and members agreed to review language collaboratively.
- The group agreed to pursue up to three omnibus questions and confirmed treasury funds can cover that cost.
55:03
Process, timelines, and next steps
The omnibus poll schedule (late March) set a near‑term timeline for finalizing language, Stockton offered to help refine submitted questions, and the team agreed to circulate drafts via email/Google Docs for group comment.
- Ed committed to draft poll questions and share them for group review.
- Jim was assigned to draft the home‑grow question for the poll.
1:02:27
Fundraising appeal and senior harm reduction initiative
The group reviewed a fundraising letter drafted by Mike promoting a senior harm reduction initiative as part of CMMNJ’s 23rd year of advocacy and requesting support for operating expenses and conference representation. The appeal lists budget items including website costs and seeks an additional $5,000 for attending legislative sessions and conferences.
- The team has a fundraising appeal to support a new senior harm reduction initiative and sustain CMMNJ operations.
- The initiative seeks an initial $5,000 to cover outreach and conference representation costs.
1:03:56
Outreach strategy and combined grant approaches
Participants discussed combining cannabis harm reduction outreach with affordable housing and disabled senior funding streams and seeking social equity funds that recognize medical cannabis patients as a priority group. The rationale presented frames program funding as preventing avoidable emergency responses through education.
- The program will emphasize "go low and slow" and practical harm-reduction steps to reduce unnecessary 911/EMT involvement and municipal costs.
1:06:13
Presentation materials and partner delivery
A member reported an existing hour-long PowerPoint, "Medical Cannabis for Senior Citizens," that can be updated and edited into a short module to integrate with other presentations. The team discussed delivering content to senior groups, churches, and municipalities and showing cost-savings to local services.
- An existing hour-long "Medical Cannabis for Senior Citizens" presentation is available and can be edited into shorter modules for partners.
1:08:03
Greenout concept and harm-reduction model
The group introduced and defined "greenout" as an overconsumption reaction and discussed harm-reduction responses including calming, monitoring, and support modeled on psychedelic harm-reduction approaches. They emphasized educating seniors about euphoria as an unexpected risk and preparing responsible supporters to hold and reassure affected individuals.
1:10:53
Regulatory updates and CRC testimony
Participants discussed firearm policy developments and a new ATF interim final rule updating the definition of unlawful controlled-substance users, noting Federal Register publication timing and related court activity. Members referenced their CRC testimony recordings and noted the next CRC meeting on February 12th.
- A new ATF interim final rule about firearms and unlawful controlled-substance users will be published in the Federal Register (noted January 21).
1:15:33
Logistics, chat/link posting, and bill tracking
A participant accidentally posted a set of bill links and then guided others to the chat where links and agenda items (including many cannabis-related bills) were available for review. The team noted the large agenda for CRC and that multiple cannabis-related bills were introduced recently.
- The Cannabis Regulatory Commission (CRC) hearing videos containing member testimony are available and the next CRC meeting is scheduled for February 12th.
1:19:29
Question drafting, Stockton coordination, and insurance discussion
The group agreed to submit questions to Stockton, requested clarity on word/character limits, and planned to provide multiple draft lengths for flexibility. One member volunteered to draft and forward proposed questions in the morning, and another committed to asking "the shell" to write the insurance question; the insurance discussion focused on state programs versus commercial health insurance.
- The team plans to submit questions to Stockton and will prepare multiple draft lengths and an insurance question for review.
1:26:51
Insurance entry point and initial framing
The group discussed using worker's compensation coverage as a strategic entry point to persuade insurers like Aetna to cover similar treatments, and the idea that a clever survey question could frame coverage as "already covered by workers comp" to influence perceptions.
- Worker's compensation coverage for treatments was discussed as a potential entry point to persuade larger insurers to cover similar therapies.
- A 65-question psychedelic survey collected about 1,200 responses but the results remain unpublished and require follow-up analysis or dissemination.
1:27:52
Psychedelic survey design and dissemination
Participants reviewed a previously circulated 65-question psychedelic survey, noted roughly 1,200 responses are stored but unpublished, and debated survey sharing, dissemination, and the limitations of its non-random sampling.
1:28:31
Survey validity and outreach tactics
The team acknowledged the survey's lack of scientific validity but discussed using concise, educational questions for policy influence; Jim Miller suggested public polling and outreach tactics as non-scientific but persuasive methods.
- Participants acknowledged the survey lacks scientific validity due to non-random sampling but saw value in targeted question wording for policy influence.
- Jim Miller proposed conducting visible public outreach at U.S. Post Offices to gauge and amplify public opinion and prompt constituent contact with legislators.
1:30:52
Technical/logistical meeting issues and bill highlights
Participants experienced audio and chat issues while shifting to legislative topics, and noted multiple New Jersey bills including a university hospital medical cannabis pilot and penalties for smoking on public beaches.
- The group identified AR 26 (de-scheduling marijuana) and other New Jersey bills as priorities for support and advocacy.
1:33:50
De‑scheduling strategy and executive action
The group examined the legal pathway to state de‑scheduling, discussed the CREMA Act’s scope, identified Consumer Affairs as the department involved, and concluded the governor could order de‑scheduling per court guidance.
- Participants discussed using recent court guidance to urge the governor or Consumer Affairs to de‑schedule marijuana at the state level.
1:36:08
Reviving prior advocacy and writing to the governor
Participants agreed older letters and materials on the CMMNJ blogspot could be revived and resent to the new governor; Jim Miller offered to draft or review a letter to press the administration on de‑scheduling and policy inconsistency.
- The team plans to revive and resend previously drafted advocacy letters from the CMMNJ blogspot to the new governor and administration.
1:39:25
Patient testimony and escalation urgency
Ryan Chase joined late and delivered a detailed personal account of harm from inability to grow medical cannabis, reported enforcement encounters, and urged the group to escalate pressure on legislators and the Senate President to prioritize medical cultivation rights.
- A new attendee described severe personal harm from being unable to legally cultivate medical cannabis and urged stronger advocacy and pressure on legislators.
1:42:45
Praise for testimony and call to action
Jim Miller praised the strength of an individual's personal testimony and argued it could serve as a powerful public service announcement and advocacy tool. He urged packaging testimony (including video attachments) and delivering it to local elected officials to prompt staff engagement.
- Jim Miller recommended using personal testimony and video attachments to increase the effectiveness of letters to elected officials.
1:43:56
Jim's past advocacy tactics and offer to represent
Jim described past tactics of hand-delivering constituent letters in Washington to gain access and recounted being arrested during advocacy actions to underscore commitment and experience. He offered to represent meeting participants and requested contact details for follow-up.
- Jim offered to represent affected patients and hand-deliver constituent letters to legislators to secure meetings with staff.
1:46:58
Ryan’s frustration with current policy and personal stakes
Ryan expressed strong frustration with New Jersey cannabis policy, criticizing the emphasis on commercial retail and lack of home cultivation rights for disabled veterans and medical patients. He highlighted accessibility issues at dispensaries and the perceived inadequacy of a medical card in protecting parents or enabling cultivation.
- Ryan Chase reported that he has written letters to state legislators and the President but felt ignored and unwilling to continue direct outreach alone.
- Ryan emphasized that New Jersey allows widespread retail dispensaries but still prohibits personal backyard cultivation for patients.
1:52:10
Equity, licensing, and skepticism about advocacy impact
Ryan voiced anger about commercial licenses being awarded under social-equity criteria while patients remain unable to grow at home, and he questioned whether testifying or writing would change legislative outcomes. Other participants pushed back, arguing public testimony and constituent stories can influence hearings.
1:54:10
Agreement to share materials and exchange contact information
Participants requested Ryan share his letters and agreed to exchange email addresses and links to review his materials. Ryan confirmed he would send the letter he sent to the President and a conference room participant said they would review it and follow up.
- Ryan committed to sharing the letter he sent to the President with the group for follow-up.
- A conference room participant agreed to review Ryan’s materials and pursue follow-up based on that information.
1:54:38
Emotional reactions and closing reflections on advocacy fatigue
The group expressed empathy for Ryan’s frustration and noted the emotional toll of advocacy work, with Jim and others expressing disappointment that a veteran with voice appears to have stepped back from public fight. Participants reiterated a preference for mounting testimony-driven advocacy using patient stories to make legislators care.
- Participants agreed that public legislative testimony (with press present) carries more weight than written documents that can be ignored.
1:57:47
Home-grow canopy and plant-count discussion
The team discussed home-grow norms and rationale for using canopy area rather than plant counts, proposing a 100 sq. ft. (10x10) canopy and noting that canopy limits allow mixed cultivars suitable for diverse patient needs. The group compared canopy sizing to six–ten plants and discussed potential yields by experienced growers.
- The group proposed a 100 sq. ft. (10x10) canopy as a practical home-grow standard equivalent to six–ten plants.
- A 10x10 canopy was affirmed as a reasonable starting point and comparable to six–ten plants in yield.
1:59:21
Event sign-ups and logistics (Morristown Day, Pride)
Participants confirmed signups for two community events: Morristown Day (June 6) and Asbury Park Pride (June 7), discussed setup and fair hours (arrive by 8:00; fairs approx. 9:00–16:00), and noted plans to recruit volunteers to staff both events. The conversation named likely volunteers and attendees present or leaving the meeting.
- The coalition will staff two community events: Morristown Day on June 6 and Asbury Park Pride on June 7, with setup around 8:00 and fairs running roughly nine to four.
- Organizers plan to recruit volunteers to staff the booths at both events.
2:00:44
Textbook call for chapters — scope and outreach request
A participant proposed distributing a call for chapter authors via the coalition list and offered to email interested people the submission link, explaining the project scope and the academic nature of the textbook. The timeline and proposal requirements were stated, including a 1,200-word proposal and subsequent chapter deliverables tied to payment.
- The textbook project is soliciting chapter proposals, with a 1,200-word proposal deadline of February 18 and paid chapters (payment and timeline referenced).
2:01:46
Deadlines, compensation, and project scale
The group clarified submission timing: a February 18 initial proposal deadline and later chapter deadlines with payment referenced; they reported a much larger-than-expected response and discussed possibly splitting the work into two volumes due to volume (about 60 chapters).
- The textbook has received a large response and may require splitting into two volumes, with submissions around 60 chapters and additional pending.
2:02:36
Legal, confidentiality, and content guidelines for chapters
Participants debated legal risks and anonymity: psychedelics remain Schedule I, but the textbook is academic and peer-reviewed; the group agreed authorship can include anonymized patient experiences and that outreach must state HIPAA compliance and anonymization to avoid solicitations of personal illegal-use confessions.
- Contributors and patient narratives will be anonymized and HIPAA-compliant; the team requested that outreach materials state this explicitly.
2:08:47
Content diversity and recruitment details
The team discussed the breadth of potential chapters—clinical, journalistic, advocacy, and patient narratives—and the involvement of medical students to collect sanitized medical histories for patient chapters, with examples such as autism-focused research and parent interviews being potential content.
2:14:32
Miscellaneous follow-ups and final remarks
The meeting closed with topic tangents including whether ibogaine counts as a psychedelic, referrals to potential authors or subjects, recognition of published work by members, and candid comments about advocacy timelines and local context for cannabis policy work.
2:17:23
HomeGrow advocacy and credibility
The team argued HomeGrow strengthens patient credibility and access, asserting medical marijuana cards add legitimacy and noting the legislature is focusing on illicit market enforcement without lowering barriers for patients. The speaker positioned HomeGrow as a central goal within their advocacy objectives.
- Participants believe current state action targets illicit markets without reducing patient access barriers.
2:18:18
HomeGrow logistics, caregiver grows, and access models
The discussion covered HomeGrow as harm reduction, the cost and skill barriers of commercial grows, and caregiver or commercial sectioned grows as alternatives used in other states like Michigan to serve patients who cannot or will not grow themselves. Participants estimated a minority of patients would both want and be skilled to grow medical-quality cannabis.
- Caregiver grows or commercially sectioned per-patient grows were proposed as feasible access models used elsewhere (example: Michigan).
2:19:29
Safety requirements for home cultivation
Speakers emphasized access provisions for patients lacking skills or funds and insisted authorized home grows must be indoors for safety because cannabis plants can bioaccumulate soil contaminants. The group reiterated the public-safety framing for HomeGrow separate from recreational use.
- Home cultivation should be indoors for safety due to bioaccumulation risks in soil.
- HomeGrow was framed primarily as a harm-reduction and patient-access policy, not a recreational policy.
- Making tinctures or concentrates at home was discussed as a logical derivative argument supporting HomeGrow.
2:22:01
Cultivar/terminology discussion
Participants debated proper terminology for cannabis varieties, settling on "cultivar" or "varieties" rather than "strain," and noted prohibition produced numerous hybrids that complicate simple sativa/indica distinctions. The group clarified cultivar versus strain usage with examples.
2:23:16
Meeting logistics and participant technical issues
The conversation included technical interruptions—Mike’s distant microphone and video issues—and light social remarks about lunchtime, which briefly paused substantive discussion. Participants acknowledged connection problems and moved on shortly after.
2:24:19
Outreach to CRC commissioner and group correspondence
A participant reported sending and replying to a letter to the CRC commissioner, thanked him for a response, and noted the commissioner expressed willingness to meet with the group though no date was set yet. The speaker emphasized wanting to press the commissioner on making medical cards more attractive and accessible.
2:25:59
Consumption methods, home preparations, and product standards
The group discussed home tinctures, rosin presses, and vaporizers; one participant intends to buy a press and another said producing tinctures from legally purchased cannabis is legally defensible if receipts are retained. They distinguished vaping from smoking, noted vaping offers easier titration, and referenced testing and organic/anti-pesticide standards for ATCs and dispensed flower.
- Vaping was distinguished from smoking and promoted for easier titration of doses.
- One participant asserted that producing cannabis-based tinctures from legally purchased cannabis is legal if receipts are kept.
2:33:45
Violent language and immediate concern
The group reacted to a participant's hostile language, describing it as a "pissing contest" and noting explicit references to "homicide." Attendees debated whether the speaker meant violence or self-harm and expressed alarm about possible escalation. [1941–1949]
- A participant used violent language ("homicide"), prompting concern and calls for intervention or caution.
- Attendees debated whether the individual's intent was self-harm or violence, noting possible confusion between "homicide" and "suicidal" language.
2:34:15
Responses, recovery perspective, and requests for accountability
Conference room participants urged the speaker to show constructive action and criticized persistent whining, citing recovery experience as rationale for direct feedback. The group discussed redirecting the conversation toward positive steps and practical solutions. [1952–1961]
- The group emphasized offering practical, recovery-based responses rather than enabling rage or attention-seeking behavior.
2:34:54
Political strategy and publicity concerns
EdR and others argued that high-profile enforcement or violence would attract legislative attention, mentioning potential arrests and publicity as catalysts for change. Several attendees discussed leveraging incidents to highlight regulatory failures. [1962–1969]
2:35:52
Correspondence with the President and industry influence
Attendees discussed letters to the President, skepticism about effectiveness, and specifically alleged that Trulieve's owner made large donations correlating with rescheduling outcomes. The group debated motives for donations and possible leaks of industry letters. [1970–1999]
- Participants suspect that a donation from the Trulieve owner influenced federal rescheduling outcomes.
2:38:59
Home-grow policy, law enforcement, and municipal concerns
The group examined Florida's unique prohibition on home grow compared with adult-use states, explored law enforcement and municipal opposition, and proposed framing legalization as harm reduction and cost-saving for emergency services. [2009–2029]
- Florida is identified as an outlier that prohibits home grow while other adult-use and medical states allow it.
- Framing home grow as harm reduction and municipal cost savings was proposed to persuade local jurisdictions and lawmakers.
2:41:12
Attendee roll call and list clean-up
Participants reviewed and confirmed the meeting attendee list, named individuals present, and resolved minor confusion about missing names and images. The group ensured all expected members were accounted for. [2030–2067]
- The meeting reviewed the attendee list and confirmed participants before adjourning.
2:42:45
Chat/tech issues, follow-ups, and adjournment
Technical issues with chat and scrolling were reported, Jared's drop-off was noted, and communication preferences were discussed. A participant said they would forward Ryan's letter, and the meeting ended with a motion to adjourn. [2069–2100]
